re: Ann: Final Data Confirms Successful PAT-S... one by one, the...

re: Ann: Final Data Confirms Successful PAT-S... one by one, the competition failed:

"On average each patient had received five prior lines of therapy, including proteasome inhibitors, immunomodulatory drugs or stem cell transplantation."


one by one, the competition was shamed. Their products outright dangerous:

"adverse immune reactions to existing marketed antibodies is known to limit the effectiveness of these treatments."


Then, PAB saved lives:

"It was shown conclusively that PAT-SM6 specifically targeted and bound to the myeloma cells."


Then, PAB kicked into high gear...

"PAT-SM6 may act synergistically with proteasome inhibitors (such as Carfilzomib) to induce better clinical responses. Such a hypothesis will be tested in Patrys’ next clinical trial in which PAT-SM6 will be used in combination with Amgen’s Carfilzomib."


PAB has extended & reinforced it's position, making Amgen look good:

"....results obtained in this trial strongly support further evaluation of PAT-SM6 in combination with Carfilzomib which is the basis of our planned Amgen sponsored clinical trial.”






This result shows the class of it's offering.

Money wise, this single product alone out of PAB's repertoire is "significantly meaningful":

The Multiple Myeloma Drug Market Will Experience Significant Growth, Increasing From $4.4 Billion In 2011 To $7.2 Billion In 2021.

Source-
http://decisionresources.com/News-and-Events/Press-Releases/Multiple-Myeloma-100212


Such continually released results slam the dots into place. Amgen has a vested interest in the product. A success for Patrys, is a success for Amgen. Big players have banked on this for a reason....



Too long; Didn't Read (tl;dr) ?

Fantastic clinical results, reinforcing PAB/Amgen's position. Is representative of PAB's entire class of products. Win.